SPONSOR
GI Innovation, Inc.
Total Trials
3
Recruiting
3
Phases
Phase 1, Phase 2, Phase 2
Conditions studied: Advanced Solid TumorMetastatic Solid TumorNon-small Cell Lung Cancer (NSCLC)Head and Neck (HNSCC)Pancreatic CancerRenal Cell Carcinoma (RCC)Cancer SurvivorsHealthy ParticipantElderlySoft Tissue Sarcoma (STS)
GI Innovation, Inc. is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancer (NSCLC), Head and Neck (HNSCC).
The trial portfolio spans Phase 1, Phase 2, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — GI Innovation, Inc.
How many clinical trials has GI Innovation, Inc. sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by GI Innovation, Inc., of which 3 are actively recruiting participants. These trials cover conditions including Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancer (NSCLC). Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does GI Innovation, Inc. research focus on?
GI Innovation, Inc. clinical trials span Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancer (NSCLC), Head and Neck (HNSCC), Pancreatic Cancer, and additional conditions. The research pipeline includes Phase 1, Phase 2, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a GI Innovation, Inc. clinical trial?
To participate in a GI Innovation, Inc. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all GI Innovation, Inc. trials with current recruitment status updated daily.
Clinical Trials by GI Innovation, Inc.
NCT07172802 Phase 1, Phase 2
Recruiting
A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Advanced Solid Tumor
NCT07363057 Phase 2
Recruiting
A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer Survivors
Cancer Survivors
NCT05824975 Phase 1, Phase 2
Recruiting
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Advanced Solid Tumor
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology